Unicycive Therapeutics, Inc.

NASDAQ:UNCY

Biotechnology

Healthcare
$3.53 -3.40%

-$0.24 today

Market cap
$103.02M
Beta
1.73
P/E (TTM)
-40.8
EPS (TTM)
-$0.17
52W Low $3.71High $8.74

Volume 0.86M

Average 0.65M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$31.32M

FY 2025 · Annual

Investing Cash Flow

-$12.10M

FY 2025 · Annual

Financing Cash Flow

$46.47M

FY 2025 · Annual

+3.1% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(10.02M)(18.06M)(30.54M)(36.73M)(26.56M)
Depreciation & Amortization13K161K284K428K572K
Deferred Income Tax00000
Stock-Based Compensation966K1.05M1.77M2.35M2.64M
Change in Working Capital(105K)1.18M(93K)(427K)(5.95M)
Accounts Receivables00000
Inventory00000
Accounts Payables1.24M1.27M1.28M790K(2.51M)
Other Working Capital(1.35M)(89K)(1.37M)(1.22M)(3.45M)
Other Non-Cash Items3.38M21K10.3M5.8M(2.02M)
Operating Cash Flow(5.77M)(15.65M)(18.28M)(28.58M)(31.32M)
Capital Expenditures(29K)(2K)(12K)(72K)(24K)
Acquisitions (Net)00000
Purchases of Investments0000(12.07M)
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(29K)(2K)(12K)(72K)(12.1M)
Debt Repayment(15K)0000
Common Stock Issued22.27M11K0683K48.08M
Common Stock Repurchased00000
Dividends Paid000(1.1M)0
Other Financing Activities119K(482K)(2.65M)(4.5M)(1.61M)
Financing Cash Flow22.38M(471K)27.54M45.09M46.47M
Effect of Forex Changes00000
Net Change in Cash16.58M(16.12M)9.25M16.44M3.06M
Free Cash Flow(5.8M)(15.65M)(18.3M)(28.65M)(31.34M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$26.6M
+ D&A$572.0K
+ Stock-Based Comp$2.6M
+ Deferred Tax$0
- Working Capital-$6.0M
- Other Non-Cash-$2.0M
= Operating Cash Flow-$31.3M
- Capex-$24.0K
= Free Cash Flow-$31.3M

Analysis

FY2025 free cash flow is -$31.3M. FCF conversion is 118.0% of net income. Operating cash flow was -$31.3M, with capex of -$24.0K. The largest bridge item is Working Capital at -$6.0M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipOct 29, 2026
3Initial statement of beneficial ownershipOct 1, 2026
8-KCurrent reportSep 29, 2026
8-KCurrent reportSep 28, 2026
SC 13G/ASC 13G/A filingAug 14, 2026

Does UNCY generate free cash flow?

Unicycive Therapeutics, Inc. (UNCY) generated -$31.34M of free cash flow in fiscal 2025.

How much operating cash flow does UNCY produce?

Operating cash flow was -$31.32M, before capital expenditures of $24,000.00.